For now, anyway, per the Associated Press. Reason given: In clinical trials of rimonabant (trade names: Acomplia and Zimulti) it was found that 88 percent of those reporting psychiatric problems (including suicidal feelings) while on the drug had no prior history of depression, strongly suggesting causality.
The unanimous finding by the expert panel’s 14 voting members made it unlikely the Food and Drug Administration will approve the drug. The agency usually follows its panel’s advice, but it isn’t required to do so.
“There is a reasonable suspicion we better learn some more and watch this affair more closely before we launch into massive use of this drug,” said panelist Dr. Jules Hirsch, of The Rockfeller University.
I knew there was a reason I dug Dr. Hirsch.
So at least we can rest easy that they’re not going to stuff all us fatties with a pill that removes all our pleasure in eating. Or sex. Or life.
The search for the magic words that will destroy all fat folks’ pleasure in living, however, continues apace. Wheee.